Anchored Multiplex PCR (AMP) for Targeted NGS (RUO): Use Cases, Design Constraints, and Interpretation Pitfalls

Anchored Multiplex PCR (AMP) has a clear place in research-use-only targeted next-generation sequencing, but its value appears only when the project question truly fits its one-sided enrichment logic. AMP is most useful when one sequence end is known while the adjacent sequence, breakpoint neighborhood, or partner region is not fully predefined. In that setting, it can recover informative molecules that conventional paired-primer amplicon designs may miss, because conventional multiplex PCR generally assumes that both flanking primer-binding regions are already known. The original AMP method paper established this concept by showing how anchored enrichment could recover rearrangement-related sequence without requiring prior knowledge of the distal partner, which remains the core reason AMP is still relevant for discovery-oriented RUO workflows.

For research teams, the right question is not whether AMP is broadly powerful, but whether the biological problem contains a real known–unknown boundary. When that boundary exists, AMP can be the better fit. When the target is fully known and both sides can be covered cleanly by paired primers, simpler multiplex PCR is often easier to design, scale, and interpret. This distinction matters for early-stage assay planning, especially when the workflow may later branch into related formats such as Targeted Region Sequencing or Amplicon Sequencing Services, where the project remains targeted but does not necessarily require an anchored design.

Figure 1. Conventional multiplex PCR versus AMP. The figure contrasts bounded paired-primer enrichment with a known-end plus anchor-enabled strategy for recovering informative adjacent sequence when the distal side is not fully predefined.

What "Anchored" Changes: Conceptual Model vs Conventional Multiplex PCR

In conventional multiplex PCR, enrichment begins with two gene-specific primers that bracket a predefined target. This works well when the problem is fully bounded: hotspot genotyping, short amplicon panels, tiled assays, or any target whose flanking regions are both known and stable. AMP changes that logic. Instead of depending on two gene-specific primers, it uses a known-side primer together with an anchor-enabled or adapter-associated amplification strategy on the opposite side. In practical terms, AMP asks a one-sided question: starting from this known sequence, what informative adjacent sequence can be recovered?

That change is useful when the project is asymmetric by nature. You may know one region confidently but not know what lies next to it. You may suspect an unknown adjacent sequence, an unexpected fusion partner, or a rearranged local context that prevents a standard paired-primer design. In those cases, anchored enrichment lowers the amount of distal sequence knowledge required before library construction. Technical descriptions of commercial AMP implementations also show that anchored workflows often rely on barcoded adapters, nested amplification, or universal primer logic, which helps convert a one-sided biological question into a sequenced library.

The most important boundary is conceptual, not promotional. AMP is not a universal upgrade. It is a targeted method that becomes worthwhile when ordinary paired-primer targeting is constrained by sequence uncertainty on one side. Broad reviews of amplicon-based enrichment have noted that PCR-based targeted methods can be fast and efficient, but still face issues such as uneven coverage, dropout, and artifact sensitivity, especially as design complexity increases. That trade-off matters in AMP because the gain in discovery flexibility comes with greater design and interpretation burden.

Another common misunderstanding is that "anchored" means "design-light." It does not. The known-side primer still determines what enters the assay. Off-target priming, local sequence complexity, primer interactions, and homologous loci still influence what kinds of reads appear downstream. Although not AMP-specific, variant-aware and specificity-focused primer design tools are useful because they formalize risks that still affect anchored assays. Work on multiplex primer design and specificity analysis remains relevant here for exactly that reason: the chemistry changes, but primer discipline does not.

When to Choose AMP: Decision Checklist (Fast)

A practical AMP decision can often be made quickly if the team asks the right questions early.

First, is there a known end but an unknown adjacent sequence that matters to the project? If yes, AMP becomes a plausible choice. If the full target is already bounded by known primer sites, an ordinary targeted assay is usually easier to justify.

Second, do you need to recover sequence across a breakpoint-like boundary, junction, or rearranged neighborhood where the distal side is uncertain? That is one of AMP's clearest research-use-only strengths because paired-primer assays generally require both sides to be predefined.

Third, is there high homology around the target that makes standard paired-primer placement difficult? AMP does not eliminate homology risk, but it can reduce the need to place two gene-specific primers in an unfavorable sequence context.

Fourth, is the project discovery-oriented rather than purely confirmatory? AMP is better aligned with candidate-event recovery and adjacency discovery than with the cheapest possible confirmation of a fully defined short target.

Fifth, can the team support a more explicit analysis model? AMP typically requires clear filtering logic, event clustering, and evidence grading. Without that downstream structure, the assay may generate more ambiguity than insight.

Sixth, is a pilot phase feasible? For many AMP projects, a small pilot is the most cost-effective part of the whole workflow because it exposes background behavior, enrichment efficiency, and repeatability before scale-up.

Seventh, are inputs and deliverables defined early enough? AMP projects benefit from unusually clear scoping: known-end target list, reference version, expected event class, raw-data handoff, summary fields, and what counts as a verification-worthy candidate. Teams that want to tighten this early alignment often benefit from reviewing how deliverables and specs are defined end-to-end before finalizing assay scope.

This is also the point where natural service choices become clearer. If the question is still mainly bounded and panel-like, Gene Panel Sequencing Service may fit better than AMP. If the project still favors a targeted PCR-first workflow but needs broader service support for library preparation and scaled execution, Multiplex PCR Sequencing is often the more direct path.

A useful "AMP before kickoff" list includes at least ten items: known-end sequence set, target molecule type, reference version, expected event class, barcode or UMI strategy if applicable, acceptable minimum evidence, desired raw-data formats, summary-report fields, control scheme, and preferred verification path. If these are vague at kickoff, the assay may still run, but the interpretation burden almost always increases.

Figure 2. RUO scoping decision tree for AMP versus conventional multiplex PCR, including checkpoints for unknown adjacent sequence, homology risk, pilot need, and longer-read escalation.

Design Constraints: Primers, Anchors, Libraries, and Controls

AMP still begins with primer quality. Even though the distal side is handled through an anchor-enabled strategy, the known-side primer governs which molecules enter the library and how selective that entry is. Weak primer placement can reduce enrichment efficiency, inflate background, create allele-specific dropout, or bias the assay toward only a subset of relevant molecules.

This is why general multiplex design logic still matters. Teams that want a deeper design comparison can review primer/panel design rules that still apply (and what changes), because many of the classic primer risks remain active in anchored workflows. Primer specificity, interaction burden, mismatch sensitivity, GC extremes, local low-complexity sequence, and predicted byproducts all remain highly relevant. Although tools such as primerJinn, Olivar, and CREPE are not AMP-specific proofs, they are still useful because they formalize the design risks that anchored assays must manage.

The anchor portion of the workflow changes library structure as well. Commercial and methodological descriptions of AMP often emphasize adapter-linked barcoding and nested or semi-nested amplification logic. That matters because barcode handling, duplicate suppression, and molecule counting can materially change interpretation. If a workflow includes UMI-like information, deduplication should be treated as a true evidence-control step rather than a cosmetic downstream filter.

Controls should be designed in from the start. At minimum, a practical RUO pilot should include a negative control, a positive or expected-support control when available, and a mixed-complexity control if the project is likely to encounter homologous or ambiguous sequence. The goal is not merely to prove that the assay produced reads. The goal is to estimate signal quality, background behavior, and repeatability under realistic conditions.

Pilot planning should be small but structured. A good pilot asks four core questions: what fraction of reads are informative, how much nonspecific background appears, how reproducible are candidate events across replicates, and what artifact classes dominate when things go wrong? Scale should be increased only after those questions have usable answers.

Design-stage constraint matrix

For teams that anticipate orthogonal follow-up, it is useful to define that path before data are generated. Simple local follow-up may be handled with Sanger Sequencing, while adjacency structures that extend beyond short-read resolution may justify Nanopore Target Sequencing as a longer-read escalation route.

Interpretation & Bioinformatics Notes (RUO): From Reads to Candidate Events

The most important interpretation rule in AMP is simple: the output is usually better treated as candidate-event evidence than as a direct final conclusion. Anchored enrichment helps recover informative reads, but the final meaning depends on mapping quality, artifact control, duplicate handling, and whether multiple evidence types converge on the same candidate event. This is why AMP projects need a reporting language built around evidence strength rather than flat present/absent statements.

At the read level, useful evidence may include split-read support, recurrent anchored-support patterns, stable adjacency coordinates, and concordant molecule families when barcodes are available. Weak evidence includes isolated low-support reads, repetitive-sequence alignments, low-complexity sequence, homologous placements, and signals that appear only in heavily duplicated libraries. Fusion-calling and targeted-PCR analysis literature consistently shows that alignment context and filter design matter at least as much as raw read count.

A practical filtering framework often contains five layers:

• Library-level QC: total reads, duplicate burden, control behavior, and enrichment profile
• Read-level QC: mapping quality, primer proximity, barcode consistency if used, artifact removal
• Event clustering: grouping reads into recurrent coordinates or adjacency patterns
• Artifact review: homology, low complexity, repetitive sequence, strand anomalies, recurrent noise signatures
• Confidence grading: high-confidence, review-needed, or low-confidence/noise

That last step is where many projects drift into overinterpretation. A more reliable practice is to classify outputs explicitly. High-confidence candidates show coherent support, acceptable mapping context, and reproducibility. Review-needed candidates show plausible support but unresolved ambiguity. Low-confidence candidates are dominated by background, weak counts, or unstable mapping context.

Where barcode-aware workflows are used, molecule-aware interpretation becomes essential. Two hundred reads derived from a small number of original molecules should not be treated as equivalent to two hundred independently tagged molecules. Related targeted enrichment work using duplex-UMI logic reinforces the same principle: original-molecule information can materially improve artifact suppression and confidence grading.

This is also where bioinformatics support should become visible in the navigation structure. A method-aware Variant Calling workflow can help formalize filtering logic and traceable output fields. For projects where short-read ambiguity remains unresolved, a longer-read follow-up route such as Nanopore Target Sequencing or Nanopore Amplicon Sequencing can be useful for escalation rather than as a first-line replacement.

Teams that expect higher background or uneven enrichment should also review QC and troubleshooting for dropout/background reads, because AMP failures often look like noisy success rather than clean failure.

Figure 3. AMP interpretation workflow from raw reads to confidence tiers, showing how QC filters, artifact review, and event clustering separate high-confidence candidates from review-needed signals.

Recommended Reporting Package for RUO AMP Projects

A useful AMP deliverable is not just a narrative summary. It should be a structured data package that lets the downstream scientist see what was done, inspect the evidence basis, and reproduce the interpretation. That matters especially for M-02-style reviewers, who typically care about raw-data structure, traceability, filtering logic, and whether summarized findings can be connected back to read-level support.

At minimum, the summarized reporting layer should include sample identity, library identity, reference version, known-end target, candidate event or adjacency definition, support counts, unique molecules where applicable, confidence tier, filter logic, and verification path. This turns the report from a static document into a reusable handoff artifact.

Reusable reporting table skeleton

The raw or near-raw handoff should be equally intentional. FASTQ/BAM conventions, barcode retention, deduplicated versus non-deduplicated counts, and the linkage between summary rows and supporting evidence should all be clear. For projects that may later expand into adjacent use cases, selective navigation is usually better than overlinking. Depending on downstream direction, the reporting framework may connect naturally to CRISPR Sequencing or Viral Genome Sequencing. Teams that need a broader discussion of end-to-end handoff standards should also align with how deliverables and specs are defined end-to-end, which is the closest planned matrix page for raw-data and reporting consistency.

Troubleshooting: Compact Matrix for Fast Review

FAQ

1) When does AMP make the most sense?

AMP is most useful when one sequence end is known but the adjacent sequence or partner region is not fully predefined. That is the situation where its one-sided enrichment logic offers a real advantage.

2) Does AMP remove the need for careful primer design?

No. The known-side primer still determines what enters the assay, so specificity, mismatch risk, local sequence context, and multiplex burden remain important.

3) Should an AMP project include a pilot?

Usually yes. A pilot is one of the fastest ways to estimate enrichment efficiency, background, repeatability, and artifact classes before scale-up.

4) Are UMIs or molecular barcodes useful in AMP?

Often yes, especially when duplicate suppression and molecule-level evidence matter. Barcode-aware interpretation is much more informative than raw read counting alone.

5) What is the biggest interpretation mistake in AMP?

Treating every supporting read as equally meaningful. Mapping context, homology, duplication, and artifact class all affect confidence.

6) When should I avoid AMP?

Be cautious when the full target is already bounded by stable primer sites and the project is purely confirmatory. In that case, ordinary multiplex PCR is often more direct and easier to interpret.

7) What should a useful AMP report contain?

At minimum: sample and library IDs, reference version, known-end target, candidate event or adjacency definition, support counts, unique molecules when available, confidence tier, key filters, and verification path.

8) What should I ask a provider before kickoff?

Ask about known-side primer strategy, control design, barcode handling, raw-data package, evidence-tier definitions, version traceability, and the planned route for orthogonal verification.

References

1. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine. 2014;20:1479-1484. DOI: 10.1038/nm.3729
2. García-García E, Carbonell-Sahuquillo S, Fuster-Tormo F, et al. Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology. Diagnostics. 2022;12(7):1539. DOI: 10.3390/diagnostics12071539
3. Cheng Y-W, Meyer A, Jakubowski MA, et al. Gene Fusion Identification Using Anchor-Based Multiplex PCR and Next-Generation Sequencing. The Journal of Applied Laboratory Medicine. 2021;6(4):917-930. DOI: 10.1093/jalm/jfaa230
4. Balan J, Jenkinson G, Nair A, et al. SeekFusion—A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA. Frontiers in Genetics. 2021;12:739054. DOI: 10.3389/fgene.2021.739054
5. Peng Q, Xu C, Kim D, Lewis M, DiCarlo J, Wang Y. Targeted Single Primer Enrichment Sequencing with Single End Duplex-UMI. Scientific Reports. 2019;9:4810. DOI: 10.1038/s41598-019-41215-z
6. Limberis JD, Metcalfe JZ. primerJinn: a tool for rationally designing multiplex PCR primer sets for amplicon sequencing and performing in silico PCR. BMC Bioinformatics. 2023;24:468. DOI: 10.1186/s12859-023-05609-1
7. Pitsch JW, Wirth SA, Tebo AG, et al. CREPE (CREate Primers and Evaluate): A Computational Tool for Large-Scale Primer Design and Specificity Analysis. Genes. 2025;16(9):1062. DOI: 10.3390/genes16091062